Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.

Inclusion Criteria:

• Currently on chronic transfusion therapy.
• Duration of chronic transfusion >1 year.
• Age 2 to 25 years
• On deferasirox monotherapy for the duration of the study.
• Informed consent from legal guardian and/or patient.
• On deferasirox for a minimum of 3 months at start of study.

Exclusion Criteria:

• Sickle cell disease or sickle-beta zero genotype.
• Combination of deferasirox and another iron chelator.

Transfusion Dependent Anemia